The FDA has approved the CAR T - cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B - cell lymphomas in adults who have failed or relapsed after two or more prior treatments. (cancernetwork.com)
Kite Pharma today reported positive 6 - month data from its pivotal ZUMA - 1 trial for its lead chimeric antigen receptor (CAR) T - cell candidate axicabtagene ciloleucel (formerly KTE - C19) in patients with chemorefractory aggressive B - cell non-Hodgkin lymphoma (NHL). (genengnews.com)
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment. (cityofhope.org)